When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Valo Health is eligible for a further $1.9 billion in potential milestone payments for up to nine new drug programs "Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact -- Update," at ...

The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Therefore, it’s no surprise that Novo Nordisk has been working on its next-generation successor, CagriSema. This product combines semaglutide, the main ingredient from Ozempic and Wegovy ...

London's Heathrow Airport built a stage to showcase emerging British performers for the first time this summer. The program was so successful the airport hopes to bring it back in 2025. Nashville ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... calling the shift a "No.1 objective". category Dollar dips towards one-week low as market ponders proposed Trump ...